Discovery of non-ETS gene fusions in human prostate cancer using next-generation RNA sequencing

Genome Research

Volumn 21, Issue 1, 2011, Pages 56-67

  Pflueger, Dorothee ^a   Terry, Stéphane ^a   Sboner, Andrea ^b   Habegger, Lukas ^b   Esgueva, Raquel ^a   Lin, Pei Chun ^a   Svensson, Maria A ^a   Kitabayashi, Naoki ^a   Moss, Benjamin J ^a   MacDonald, Theresa Y ^a   Cao, Xuhong ^c   Barrette, Terrence ^c,d   Tewari, Ashutosh K ^a,e   Chee, Mark S ^f   Chinnaiyan, Arul M ^c,d   Rickman, David S ^a   Demichelis, Francesca ^a   Gerstein, Mark B ^b,g   Rubin, Mark A ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b YALE UNIVERSITY   (United States)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^e NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^f Prognosys Biosciences Inc   (United States)

^g Yale University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD9 ANTIGEN; CHIMERIC PROTEIN; I KAPPA B KINASE BETA; PROTEIN P21; TRANSCRIPTION FACTOR ER81; TRANSCRIPTION FACTOR ERG; TRANSCRIPTION FACTOR ETS; TRANSCRIPTOME;

ARTICLE; BACTERIAL GENE; CARCINOGENESIS; CONTROLLED STUDY; ERG GENE; GENE FUSION; HOMEOSTASIS; HUMAN; HUMAN TISSUE; MALE; ONCOGENE; PIGU GENE; PRIORITY JOURNAL; PROSTATE CANCER; RNA SEQUENCE; RSRC2 GENE; TMPRSS2 GENE; TUMOR SUPPRESSOR GENE;

ANTIGENS, CD; COMPUTATIONAL BIOLOGY; CYCLIN-DEPENDENT KINASE INHIBITOR P21; GENE EXPRESSION PROFILING; GENE FUSION; HUMANS; I-KAPPA B KINASE; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MEMBRANE GLYCOPROTEINS; MOLECULAR SEQUENCE DATA; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-ETS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, RNA; SERINE ENDOPEPTIDASES; TRANS-ACTIVATORS;

EID: 78651476339     PISSN: 10889051     EISSN: 15495469     Source Type: Journal    
DOI: 10.1101/gr.110684.110     Document Type: Article

References (53)

1. Berger MF, Levin JZ, Vijayendran K, Sivachenko A, Adiconis X, Maguire J, Johnson LA, Robinson J, Verhaak RG, Sougnez C, et al. 2010. Integrative analysis of the melanoma transcriptome. Genome Res 20: 413-427.
2. Bergsagel PL, Kuehl WM. 2001. Chromosome translocations in multiple myeloma. Oncogene 20: 5611-5622.
3. Burke JR, Pattoli MA, Gregor KR, Brassil PJ, MacMaster JF, McIntyre KW, Yang X, Iotzova VS, Clarke W, Strnad J, et al. 2003. BMS-345541 is a highly selective inhibitor of IkB kinase that binds at an allosteric site of the enzyme and blocks NF-κB-dependent transcription in mice. J Biol Chem 278: 1450-1456.
4. Carver BS, Tran J, Gopalan A, Chen Z, Shaikh S, Carracedo A, Alimonti A, Nardella C, Varmeh S, Scardino PT, et al. 2009. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet 41: 619-624.
5. Chariot A. 2009. The NF-κB-independent functions of IKK subunits in immunity and cancer. Trends Cell Biol 19: 404-413.
6. Dalgliesh GL, Furge K, Greenman C, Chen L, Bignell G, Butler A, Davies H, Edkins S, Hardy C, Latimer C, et al. 2010. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 463: 360-363.
7. Gerstein MB, Bruce C, Rozowsky JS, Zheng D, Du J, Korbel JO, Emanuelsson O, Zhang ZD, Weissman S, Snyder M. 2007. What is a gene, post- ENCODE? History and updated definition. Genome Res 17: 669-681.
8. Gingeras TR. 2009. Implications of chimaeric non-co-linear transcripts. Nature 461: 206-211.
9. Guo Z, Linn JF, Wu G, Anzick SL, Eisenberger CF, Halachmi S, Cohen Y, Fomenkov A, Hoque MO, Okami K, et al. 2004. CDC91L1 (PIG-U) is a newly discovered oncogene in human bladder cancer. Nat Med 10: 374-381.
10. Han B, Mehra R, Lonigro RJ, Wang L, Suleman K, Menon A, Palanisamy N, Tomlins SA, Chinnaiyan AM, Shah RB. 2009. Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression. Mod Pathol 22: 1083-1093.
11. Hermans KG, Bressers AA, van der Korput HA, Dits NF, Jenster G, Trapman J. 2008. Two unique novel prostate-specific and androgen-regulated fusion partners of ETV4 in prostate cancer. Cancer Res 68: 3094-3098.
12. Higashiyama M, Taki T, Ieki Y, Adachi M, Huang CL, Koh T, Kodama K, Doi O, Miyake M. 1995. Reduced motility related protein-1 (MRP-1/CD9) gene expression as a factor of poor prognosis in non-small cell lung cancer. Cancer Res 55: 6040-6044.
13. Huang CI, Kohno N, Ogawa E, Adachi M, Taki T, Miyake M. 1998. Correlation of reduction in MRP-1/CD9 and KAI1/CD82 expression with recurrences in breast cancer patients. Am J Pathol 153: 973-983. (Pubitemid 28419050)
14. Idris AI, Libouban H, Nyangoga H, Landao-Bassonga E, Chappard D, Ralston SH. 2009. Pharmacologic inhibitors of IκB kinase suppress growth and migration of mammary carcinosarcoma cells in vitro and prevent osteolytic bone metastasis in vivo. Mol Cancer Ther 8: 2339-2347.
15. Jinawath N, Vasoontara C, Jinawath A, Fang X, Zhao K, Yap KL, Guo T, Lee CS, Wang W, Balgley BM, et al. 2010. Oncoproteomic analysis reveals co-upregulation of RELA and STAT5 in carboplatin resistant ovarian carcinoma. PLoS ONE 5: e11198. doi: 10.1371/journal.pone.0011198.
16. Klezovitch O, Risk M, Coleman I, Lucas JM, Null M, True LD, Nelson PS, Vasioukhin V. 2008. A causal role for ERG in neoplastic transformation of prostate epithelium. Proc Natl Acad Sci 105: 2105-2110.
17. Kumar-Sinha C, Tomlins SA, Chinnaiyan AM. 2008. Recurrent gene fusions in prostate cancer. Natl Rev 8: 497-511.
18. Kurehara H, Ishiguro H, Kimura M, Mitsui A, Ando T, Sugito N, Mori R, Takashima N, Ogawa R, Fujii Y, et al. 2007. A novel gene, RSRC2, inhibits cell proliferation and affects survival in esophageal cancer patients. Int J Oncol 30: 421-428.
19. Lam LT, Davis RE, Pierce J, Hepperle M, Xu Y, Hottelet M, Nong Y, Wen D, Adams J, Dang L, et al. 2005. Small molecule inhibitors of IκB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. Clin Cancer Res 11: 28-40.
20. Levin JZ, Berger MF, Adiconis X, Rogov P, Melnikov A, Fennell T, Nusbaum C, Garraway LA, Gnirke A. 2009. Targeted next-generation sequencing of a cancer transcriptome enhances detection of sequence variants and novel fusion transcripts. Genome Biol 10: R115. doi: 10.1186/gb-2009-10-10-r115.
21. Lin C, Yang L, Tanasa B, Hutt K, Ju BG, Ohgi K, Zhang J, Rose DW, Fu XD, Glass CK, et al. 2009. Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer. Cell 139: 1069-1083.
22. Maher CA, Kumar-Sinha C, Cao X, Kalyana-Sundaram S, Han B, Jing X, Sam L, Barrette T, Palanisamy N, Chinnaiyan AM. 2009a. Transcriptome sequencing to detect gene fusions in cancer. Nature 458: 97-101.
23. Maher CA, Palanisamy N, Brenner JC, Cao X, Kalyana-Sundaram S, Luo S, Khrebtukova I, Barrette TR, Grasso C, Yu J, et al. 2009b. Chimeric transcript discovery by paired-end transcriptome sequencing. Proc Natl Acad Sci 106: 12353-12358.
24. Makkonen H, Kauhanen M, Paakinaho V, Jaaskelainen T, Palvimo JJ. 2009. Long-range activation of FKBP51 transcription by the androgen receptor via distal intronic enhancers. Nucleic Acids Res 37: 4135-4148.
25. Mitelman F, Johansson B, Mertens F. 2007. The impact of translocations and gene fusions on cancer causation. Natl Rev 7: 233-245.
26. Mori M, Mimori K, Shiraishi T, Haraguchi M, Ueo H, Barnard GF, Akiyoshi T. 1998. Motility related protein 1 (MRP1/CD9) expression in colon cancer. Clin Cancer Res 4: 1507-1510.
27. Mortazavi A, Williams BA, McCue K, Schaeffer L, Wold B. 2008. Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat Methods 5: 621-628.
28. Mosquera JM, Mehra R, Regan MM, Perner S, Genega EM, Bueti G, Shah RB, Gaston S, Tomlins SA, Wei JT, et al. 2009. Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Clin Cancer Res 15: 4706-4711.
29. Nagpal JK, Dasgupta S, Jadallah S, Chae YK, Ratovitski EA, Toubaji A, Netto GJ, Eagle T, Nissan A, Sidransky D, et al. 2008. Profiling the expression pattern of GPI transamidase complex subunits in human cancer. Mod Pathol 21: 979-991.
30. Palanisamy N, Ateeq B, Kalyana-Sundaram S, Pflueger D, Ramnarayanan K, Shankar S, Han B, Cao Q, Cao X, Suleman K, et al. 2010. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med 16: 793-798.
31. Perner S, Demichelis F, Beroukhim R, Schmidt FH, Mosquera JM, Setlur S, Tchinda J, Tomlins SA, Hofer MD, Pienta KG, et al. 2006. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res 66: 8337-8341.
32. Pflueger D, Rickman DS, Sboner A, Perner S, LaFargue CJ, Svensson MA, Moss BJ, Kitabayashi N, Pan Y, de la Taille A, et al. 2009. N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer. Neoplasia 11: 804-811.
33. Prensner JR, Chinnaiyan AM. 2009. Oncogenic gene fusions in epithelial carcinomas. Curr Opin Genet Dev 19: 82-91.
34. Quail MA, Kozarewa I, Smith F, Scally A, Stephens PJ, Durbin R, Swerdlow H, Turner DJ. 2008. A large genome center's improvements to the Illumina sequencing system. Nat Methods 5: 1005-1010.
35. Rickman DS, Pflueger D, Moss B, VanDoren VE, Chen CX, de la Taille A, Kuefer R, Tewari AK, Setlur SR, Demichelis F, et al. 2009. SLC45A3-ELK4 is a novel and frequent erythroblast transformation-specific fusion transcript in prostate cancer. Cancer Res 69: 2734-2738.
36. Sauer G, Windisch J, Kurzeder C, Heilmann V, Kreienberg R, Deissler H. 2003. Progression of cervical carcinomas is associated with down-regulation of CD9 but strong local re-expression at sites of transendothelial invasion. Clin Cancer Res 9: 6426-6431.
37. Sboner A, Demichelis F, Calza S, Pawitan Y, Setlur SR, Hoshida Y, Perner S, Adami HO, Fall K, Mucci LA, et al. 2010a. Molecular sampling of prostate cancer: A dilemma for predicting disease progression. BMC Med Genomics 3: 8. doi: 10.1186/1755-8794-3-8.
38. Sboner A, Habegger L, Pflueger D, Terry S, Chen D, Rozowsky J, Tewari AK, Kitabayashi N, Moss BJ, Chee MS, et al. 2010b. FusionSeq: A modular framework for finding gene fusions by analyzing paired-end RNA-sequencing data. Genome Biol (in press).
39. Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, et al. 2006. The consensus coding sequences of human breast and colorectal cancers. Science 314: 268-274.
40. Stephens PJ, McBride DJ, Lin ML, Varela I, Pleasance ED, Simpson JT, Stebbings LA, Leroy C, Edkins S, Mudie LJ, et al. 2009. Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature 462: 1005-1010.
41. Stratton MR, Campbell PJ, Futreal PA. 2009. The cancer genome. Nature 458: 719-724.
42. Sulong S, Moorman AV, Irving JA, Strefford JC, Konn ZJ, Case MC, Minto L, Barber KE, Parker H, Wright SL, et al. 2009. A comprehensive analysis of the CDKN2A gene in childhood acute lymphoblastic leukemia reveals genomic deletion, copy number neutral loss of heterozygosity, and association with specific cytogenetic subgroups. Blood 113: 100-107.
43. Svensson MA, LaFargue CJ, MacDonald T, Pflueger D, Kitabayashi N, Santa- Cruz A, Garsha K, Sathyanarayana U, Riley J, Yun S, et al. 2010. Testing mutual exclusivity of ETS rearranged prostate cancer. Lab Invest. doi: 10.1038/labinvest.2010.179.
44. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, et al. 2010. Integrative genomic profiling of human prostate cancer. Cancer Cell 18: 11-22.
45. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, et al. 2005. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310: 644-648.
46. Tomlins SA, Laxman B, Dhanasekaran SM, Helgeson BE, Cao X, Morris DS, Menon A, Jing X, Cao Q, Han B, et al. 2007. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 448: 595-599.
47. Tomlins SA, Laxman B, Varambally S, Cao X, Yu J, Helgeson BE, Cao Q, Prensner JR, Rubin MA, Shah RB, et al. 2008. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 10: 177-188.
48. van Bokhoven A, Varella-Garcia M, Korch C, Johannes WU, Smith EE, Miller HL, Nordeen SK, Miller GJ, Lucia MS. 2003. Molecular characterization of human prostate carcinoma cell lines. Prostate 57: 205-225. (Pubitemid 37267805)
49. Wang JC, Begin LR, Berube NG, Chevalier S, Aprikian AG, Gourdeau H, Chevrette M. 2007. Down-regulation of CD9 expression during prostate carcinoma progression is associated with CD9 mRNA modifications. Clin Cancer Res 13: 2354-2361.
50. Wu G, Guo Z, Chatterjee A, Huang X, Rubin E, Wu F, Mambo E, Chang X, Osada M, Sook Kim M, et al. 2006. Overexpression of glycosylphosphatidylinositol (GPI) transamidase subunits phosphatidylinositol glycan class T and/or GPI anchor attachment 1 induces tumorigenesis and contributes to invasion in human breast cancer. Cancer Res 66: 9829-9836.
51. Yang J, Amiri KI, Burke JR, Schmid JA, Richmond A. 2006. BMS-345541 targets inhibitor of κB kinase and induces apoptosis in melanoma: Involvement of nuclear factor kB and mitochondria pathways. Clin Cancer Res 12: 950-960.
52. Yemelyanov A, Gasparian A, Lindholm P, Dang L, Pierce JW, Kisseljov F, Karseladze A, Budunova I. 2006. Effects of IKK inhibitor PS1145 on NFκB function, proliferation, apoptosis and invasion activity in prostate carcinoma cells. Oncogene 25: 387-398.
53. Yoshimoto M, Joshua AM, Cunha IW, Coudry RA, Fonseca FP, Ludkovski O, Zielenska M, Soares FA, Squire JA. 2008. Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome. Mod Pathol 21: 1451-1460.